| Paradigm Biocapital Advisors LP |
| 6.7M |
| $123.5M |
| +113.5% |
| 7.471% |
| 2.31% |
| 5 | Kynam Capital Management, LP | 6.5M | $118.6M | +175.6% | 7.171% | 6.55% |
| 6 | STATE STREET CORP | 6.1M | $112.5M | +31.1% | 6.806% | 0.00% |
| 7 | Fairmount Funds Management LLC | 5.1M | $93.5M | +30.0% | 5.657% | 6.18% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 4.6M | $84.1M | +9.8% | 5.085% | 0.00% |
| 9 | Deep Track Capital, LP | 3.6M | $66.0M | +157.7% | 3.992% | 0.96% |
| 10 | Venrock Adviser, LLC | 3.3M | $59.8M | -16.1% | 3.620% | 1.81% |
| 11 | WELLINGTON MANAGEMENT GROUP LLP | 3.1M | $57.5M | +1.6% | 3.476% | 0.01% |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.8M | $50.6M | +67.7% | 3.059% | 0.00% |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 2.5M | $46.0M | +7.2% | 2.780% | 0.00% |
| 14 | Avoro Capital Advisors LLC | 2.5M | $45.9M | +66.7% | 2.778% | 0.41% |
| 15 | BAKER BROS. ADVISORS LP | 2.4M | $43.8M | +20.9% | 2.648% | 0.22% |
| 16 | Point72 Asset Management, L.P. | 2.4M | $43.3M | +629.9% | 2.618% | 0.05% |
| 17 | Caligan Partners LP | 2.2M | $40.3M | — | 2.438% | 1.90% |
| 18 | Novo Holdings A/S | 2.1M | $39.2M | +6.8% | 2.372% | 2.28% |
| 19 | TANG CAPITAL MANAGEMENT LLC | 1.8M | $32.9M | 0.0% | 1.992% | 1.50% |
| 20 | Fisher Asset Management, LLC | 1.8M | $32.2M | -1.0% | 1.945% | 0.01% |
| 21 | Candriam S.C.A. | 1.7M | $31.3M | +139.9% | 1.897% | 0.14% |
| 22 | GOLDMAN SACHS GROUP INC | 1.7M | $31.1M | +6.2% | 1.879% | 0.00% |
| 23 | First Turn Management, LLC | 1.7M | $30.7M | +83.3% | 1.856% | 3.28% |
| 24 | DIMENSIONAL FUND ADVISORS LP | 1.6M | $29.6M | +204.2% | 1.791% | 0.01% |
| 25 | ALLIANCEBERNSTEIN L.P. | 1.4M | $27.2M | -0.0% | 1.546% | 0.01% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in VRDN — a direct measure of their conviction.
| 141.05% |
| +1.75 pp |
| $1.19B |
| 28% |
| Q4 2024 | 175 | +8.0% | 139.30% | +2.53 pp | $1.65B | 15% |
| Q3 2024 | 162 | — | 136.77% | — | $1.94B | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
44 institutions opened new positions in VRDN during Q2 2026, while 52 fully exited. 90 added to existing positions and 79 trimmed.
VRDN institutional ownership rose by 12.81 percentage points quarter-over-quarter, with a net change of -8 holders.
The top 10 institutions account for 51.9% of all reported 13F value in VRDN, and the top 25 account for 76.2%.
Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.